Honestly it's such low hanging fruit that it will happen soon. Not worth tracking and thinking about. Mgmt has given themselves a nice bonus.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%